SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
<p>Abstract</p> <p>Background</p> <p>Chemoradiotherapy is the standard of care for patients with oesophageal cancer unsuitable for surgery due to the presence of co-morbidity or extent of disease, and is a standard treatment option for patients with squamous cell carcin...
Main Authors: | Staffurth John N, Gollins Simon, Al-Mokhtar Ruby, Griffiths Gareth O, Nixon Lisette S, Hurt Christopher N, Phillips Ceri J, Blazeby Jane M, Crosby Tom D |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-10-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/466 |
Similar Items
-
Health-related quality of Life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer
by: Hurt, Christopher N., et al.
Published: (2015) -
Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy
by: Lucy Wills, et al.
Published: (2017-11-01) -
Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
by: Il Seok Daniel Jeong, et al.
Published: (2020-08-01) -
Fatal bleeding in a nasopharyngeal carcinoma patient after concurrent chemoradiation plus cetuximab: a case report
by: Zheng LY, et al.
Published: (2013-06-01) -
The oesophagus and stress
by: Johnston, Brian Thomas
Published: (1992)